October 15, 2024: U.S. Patent No. 12,017,399 "Von Willerbrand Factor Proteins for Treating Bleeding Disorders"

Queen’s Partnerships and Innovation is pleased to report the issuance of U.S. Patent No. 12,017,399 "Von Willerbrand Factor Proteins for Treating Bleeding Disorders," on October 15, 2024 to Philip Zakas, David Lillicrap, Christopher Doering, Eric Gaucher, Caclan Radford, and Harold Trent Spencer. The patent relates to complimentary drug treatments that enhance gene therapy treatment for individuals with bleeding disorders.

U.S. Patent No. 12,017,399 (1.9 MB, PDF)